PriceTargets.com logo

Creative Medical Technology - CELZ Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.84 As of 04/19/2024 01:06 PM ET
▲ +0.03 (0.62%)

This chart shows the closing price for CELZ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Creative Medical Technology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELZ

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Creative Medical Technology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.84.

This chart shows the closing price for CELZ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Creative Medical Technology. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2022Roth CapitalInitiated CoverageBuy$100.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Creative Medical Technology logo
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Read More

Today's Range

Now: $4.84
Low: $4.81
High: $4.88

50 Day Range

MA: $5.00
Low: $4.03
High: $6.45

52 Week Range

Now: $4.84
Low: $3.93
High: $10.28

Volume

8,229 shs

Average Volume

172,525 shs

Market Capitalization

$6.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Creative Medical Technology?

The following Wall Street analysts have issued stock ratings on Creative Medical Technology in the last year:
View the latest analyst ratings for CELZ.

What is the current price target for Creative Medical Technology?

0 Wall Street analysts have set twelve-month price targets for Creative Medical Technology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Creative Medical Technology in the next year.
View the latest price targets for CELZ.

What is the current consensus analyst rating for Creative Medical Technology?

Creative Medical Technology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CELZ.

What other companies compete with Creative Medical Technology?

Other companies that are similar to Creative Medical Technology include Titan Pharmaceuticals, Chromocell Therapeutics, Fresh Tracks Therapeutics, TRACON Pharmaceuticals and Gamida Cell. Learn More about companies similar to Creative Medical Technology.

How do I contact Creative Medical Technology's investor relations team?

Creative Medical Technology's physical mailing address is 2017 W Peoria Ave, PHOENIX, AZ 85029-4916, United States. The company's listed phone number is (833) 336-7636 and its investor relations email address is [email protected]. The official website for Creative Medical Technology is www.creativemedicaltechnology.com. Learn More about contacing Creative Medical Technology investor relations.